CSL Limited (ASX:CSL) Insider Acquires A$50,012.00 in Stock

CSL Limited (ASX:CSL) insider Megan Clark bought 200 shares of the stock in a transaction on Monday, March 17th. The shares were bought at an average price of A$250.06 ($158.27) per share, for a total transaction of A$50,012.00 ($31,653.16).

Megan Clark also recently made the following trade(s):

• On Wednesday, February 19th, Megan Clark bought 132 shares of CSL stock. The stock was purchased at an average cost of A$264.85 ($167.63) per share, for a total transaction of A$34,959.94 ($22,126.54).

CSL Stock Performance

The stock has a market capitalization of $77.43 billion, a PE ratio of 28.02, a PEG ratio of 1.29 and a beta of 0.32. The company has a quick ratio of 1.68, a current ratio of 1.86 and a debt-to-equity ratio of 64.46.

CSL Increases Dividend

The firm also recently announced a Interim dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Tuesday, April 8th will be given a dividend of $2.073 per share. This represents a dividend yield of 0.81%. This is a positive change from CSL’s previous Interim dividend of $1.83. The ex-dividend date of this dividend is Sunday, March 9th. CSL’s payout ratio is presently 50.38%.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.